The USDA committed legal error by exempting “highly processed foods,” such as sugar, from being labeled as “bioengineered,” according to federal appeals court ...
On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
(Beyond Pesticides, December 17, 2025) In a 50-plus page opinion, the United States Court of Appeals for the Ninth Circuit ruled in October for the plaintiffs on providing general public access to ...
A new type of bioengineered blood vessel showed strong results in treating severe vascular injuries, potentially offering vascular surgeons a better alternative to synthetic grafts when patients' ...
Humacyte’s Symvess® is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results